Publications
69
Citations
1,067
Est. group size
—
Recurring co-author estimate
Active years
9
Publishing since 2018
Typically publishes in teams of ~18 · 9% small-team papers (≤3 authors) · across 17 venues
- Conversation with Future Clinical Cytogeneticists: The New Frontiers
Genes · 2026
- Therapy-induced rapid drug resistance driven by genome chaos and polyploid giant cancer cells
Cancer Letters · 2026
- Talquetamab–Daratumumab in Relapsed or Refractory Myeloma
New England Journal of Medicine · 2026
- Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study
The Lancet Haematology · 2025
- Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab
New England Journal of Medicine · 2025
- Characterization and Management of Cytokine Release Syndrome From the <scp>MonumenTAL</scp> ‐1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma
Cancer Medicine · 2025
- Outcomes in patients with relapsed/refractory multiple myeloma with extramedullary disease: a meta-analysis
Annals of Hematology · 2025
- Randomized, multi-center study of carfilzomib, lenalidomide, and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trial.
Journal of Clinical Oncology · 2025
- Efficacy and safety from the phase 1/2 MonumenTAL-1 study of talquetamab, a GPRC5D×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: Analyses at an extended median follow-up.
Journal of Clinical Oncology · 2025
- Talquetamab for relapsed/refractory multiple myeloma : Real-world outcomes from the US multiple myeloma immunotherapy consortium
Blood · 2025
- Long-term outcomes in Waldenström macroglobulinemia (WM) patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy.
Journal of Clinical Oncology · 2025
- POSTER: MM-215 Efficacy And Safety from the Phase 1/2 Monumental-1 Study of Talquetamab, a GPRC5D × CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma: Analyses at an Extended Median Follow-Up
Clinical Lymphoma Myeloma & Leukemia · 2025
- POSTER: MM-217 Clinical Outcomes of Patients With Relapsed or Refractory Multiple Myeloma With and Without Extramedullary Disease
Clinical Lymphoma Myeloma & Leukemia · 2025
- MM-215: Efficacy And Safety from the Phase 1/2 Monumental-1 Study of Talquetamab, a GPRC5D × CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma: Analyses at an Extended Median Follow-Up
Clinical Lymphoma Myeloma & Leukemia · 2025
- MM-217: Clinical Outcomes of Patients With Relapsed or Refractory Multiple Myeloma With and Without Extramedullary Disease
Clinical Lymphoma Myeloma & Leukemia · 2025
- Clinical Lymphoma Myeloma & Leukemia×28
- Journal of Clinical Oncology×11
- Blood×7
- HemaSphere×3
- Methods in molecular biology×3
- Attaya Suvannasankha
Medicine · Indiana University
- Matthew J. Pianko
Medicine · University of Michigan
- David F. Keren
Medicine · University of Michigan
- Erica Campagnaro
Medicine · University of Michigan
- Craig E. Cole
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile